B
Bull
Bull · 25%OCX
$12.62
Szenariopreis
$3.200
+0.551 (+17.22%)Zum Schluss
Loading chart…
- High
- 3.210
- Open
- 2.770
- VWAP
- 3.04
- Vol
- 103.56K
- Mkt Cap
- 39.02M
- Low
- 2.710
- Amount
- 314.82K
- EV/EBITDA, TTM
- -4.06
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Analyst Ratings (4)
+91.56% upside
Buy
4 Buy
0 Hold
0 Sell
Current: 3.20
Tief
4.25
Durchschnitt
6.13
Hoch
8.00
Lake Street
Buy
$8
2025-05-21
Lake Street
2025-05-21
Kursziel
$8
Buy
Needham
Strong Buy
$4.25
2025-04-08
Needham
2025-04-08
Kursziel
$4.25
Strong Buy
Lake Street
Strong Buy
$5
2025-03-28
Lake Street
2025-03-28
Kursziel
$5
Strong Buy
Stephens & Co.
Hold
$4
2025-03-26
Stephens & Co.
2025-03-26
Kursziel
$4
Hold
Needham
Strong Buy
$4.25
2025-03-25
Needham
2025-03-25
Kursziel
$4.25
Strong Buy
Bewertungskennzahlen
The current forward P/E ratio for OncoCyte Corp (OCX) is -2.17, compared to its 5-year average forward P/E of -2.37.
Alphio AI Price Scenarios for OCX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
5.005-18NewsfilterInterVenn Biosciences Appoints New Board Members
- 4.506-17Newsfilter
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
- 9.005-19Newsfilter
Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
- 9.505-12Newsfilter
Oncocyte Reports Q1 2025 Results and Business Progress
- 9.004-30Newsfilter
Oncocyte Provides Positive Update on Clinical Trial Progress
OCX FAQ — answered by Alphio AI
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).
4 analysts cover OCX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 6.13.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.